Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity

Clinical Research in Cardiology

Volumn 101, Issue 6, 2012, Pages 445-452

  Gremmel, Thomas ^a   Frühwirth, Karin ^a   Kopp, Christoph W ^a   Kaider, Alexandra ^a   Steiner, Sabine ^a   Bakchoul, Tamam ^b   Sachs, Ulrich J H ^b   Koppensteiner, Renate ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Clopidogrel; Heparin; Platelet reactivity

Indexed keywords

CLOPIDOGREL; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PADGEM PROTEIN;

ADULT; AGED; ANGIOPLASTY; ARTICLE; CARDIOVASCULAR DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; STENT; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARIN; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FACTOR 4; STENTS; TICLOPIDINE;

EID: 84863716591     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-011-0411-3     Document Type: Article

References (50)

1. Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ (2011) Heparin promotes platelet responsiveness by potentiating aIIb3-mediated outside-in signaling. Blood 117:4946-4952
2. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocyopenia. Thromb Haemost 68:95-96
3. Gruel Y, Boizard-Boval B, Wautier JL (1993) Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparinassociated thrombocytopenia. Thromb Haemost 70:374-375
4. Shantsila E, Lip GY, Chong BH (2009) Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 135:1651-1664
5. Kelton JG (2005) The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 127:9S- 20S
6. Cattaneo M (2006) P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J 27:1010-1012
7. Neubauer H, Krüger JC, Lask S, Endres HG, Pepinghege F, Engelhardt A, Bulut D, Mügge A (2009) Comparing the antiplatelet effects of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol 98:533-540
8. Möllmann H, Nef H, Böhm M, Laufs U (2009) Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association. Clin Res Cardiol 98:1-7
9. Ostad MA, Nick E, Paixao-Gatinho V, Schnorbus B, Schiewe R, Tschentscher P, Munzel T, Warnholtz A (2011) Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. Clin Res Cardiol 100:29-36
10. Diehl P, Halscheid C, Olivier C, Helbing T, Bode C, Moser M (2011) Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol 100:765-771
11. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246-251
12. Gurbel PA, Bliden KP, Etherington A, Tantry US (2007) Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 121:107-115
13. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849-856
14. Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N (2010) Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 103:151-159
15. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B (2010) Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 8:351-359
16. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L (2007) Vasodilatorstimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 5:1630-1636
17. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a pointof- care assay: a 12-month follow-up. Circulation 119:237-242
18. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46:1820-1826
19. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256-260
20. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW (2010) Calcium-channel blockers decrease clopidogrel- mediated platelet inhibition. Heart 96:186-189
21. Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, Braun S, Schulz S, Schomig A, Kastrati A (2010) Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 31:1205-1211
22. Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L (2008) Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 52:1968-1977
23. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabate M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A (2010) Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55:1139-1146
24. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW (2010) Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 8:37-42
25. Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Levy N, Maillard L, Barragan P, Dignat-George F, Camoin-Jau L, Bonello L (2009) Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 104:1511-1515
26. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362
27. Geisler T, Mueller K, Aichele S, Bigalke B, Stellos K, Htun P, Ninci E, Fateh-Moghadam S, May AE, Gawaz M (2011) Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol 99:743-752
28. Schwarz AK, Zahn R, Hochadel M, Kerber S, Hauptmann KE, Glunz HG, Mudra H, Darius H, Zeymer U (2011) Age-related differences in antithrombotic therapy, success rate and in-hospital mortality in patients undergoing percutaneous coronary intervention: results of the quality control registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). Clin Res Cardiol 100:773-780
29. Zankl AR, Andrassy M, Volz C, Ivandic B, Krumsdorf U, Katus HA, Blessing E (2010) Radial artery thrombosis following transradial coronary angiography: incidence and rationale for treatment of symptomatic patients with low-molecular-weight heparins. Clin Res Cardiol 99:841-847
30. Dziewierz A, Siudak Z, Rakowski T, Birkemeyer R, Mielecki W, Ranosz P, Dubiel JS, Dudek D (2011) Drug-eluting versus baremetal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER registry. Clin Res Cardiol 100:139-145
31. Selleng S, Malowsky B, Itterman T, Bagemuhl J, Wessel A, Wollert HG, Warkentin TE, Greinacher A (2010) Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. Am Heart J 160:362-369
32. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703-1708
33. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y (1999) Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99:2530-2536
34. Pouplard C, Regina S, May MA, Gruel Y (2007) Heparin-induced thrombocytopenia: a frequent complication after cardiac surgery. Arch Mal Coeur Vaiss 100:563-568
35. Mattioli AV, Bonetti L, Zennaro M, Ambrosio G, Mattioli G (2009) Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Am Heart J 157:589-595
36. Bennett-Guerrero E, Slaughter TF, White WD, Welsby IJ, Greenberg CS, El-Moalem H, Ortel TL (2005) Preoperative anti- PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130:1567-1572
37. Pouplard C, Gueret P, Fouassier M, Ternisien C, Trossaert M, Regina S, Gruel Y (2007) Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 5:1373-1379
38. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C (1991) A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 66:734-736
39. Morel-Kopp MC, Aboud M, Tan CW, Kulathilake C, Ward C (2010) Whole blood impedance aggregometry detects heparininduced thrombocytopenia antibodies. Thromb Res 125:e234-e239
40. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-933
41. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5:1666-1673
42. Schallmoser K, Drexler C, Rohde E, Strunk D, Groselj-Strele A, Lanzer G, Kroll H, Panzer S (2009) The particle gel immunoassay as a rapid test to rule out heparin-induced thrombocytopenia? J Thorac Cardiovasc Surg 137:781-783
43. Selleng S, Malowsky B, Strobel U, Wessel A, Ittermann T, Wollert HG, Warkentin TE, Greinacher A (2010) Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost 8:30-36
44. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y (2005) Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparindependent antibodies. Br J Haematol 128:837-841
45. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759-765
46. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD (2008) Aspirin 'resistance': role of preexistent platelet reactivity and correlation between tests. J Thromb Haemost 6:2035-2044
47. Frelinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD (2006) Residual arachidonic acidinduced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2- independent pathway: a 700-patient study of aspirin resistance. Circulation 113:2888-2896
48. Elalamy I, Galea V, Hatmi M, Gerotziafas GT (2009) Heparininduced multiple electrode aggregometry: a potential tool for improvement of heparin-induced thrombocytopenia diagnosis. J Thromb Haemost 7:1932-1934
49. Eichler P, Budde U, Haas S, Kroll H, Loreth RM, Meyer O, Pachmann U, Potzsch B, Schabel A, Albrecht D, Greinacher A (1999) First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 81:625-629
50. Behr T, Kuch B, Behr W, von Scheidt W (2011) Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clin Res Cardiol 100:907-914